Table 3.
Authors | Clinical or Experimental Condition | Species | Treatment Scheme | Major Outcome |
---|---|---|---|---|
Chhetry et al, 2016 [143] | MDD | Human | 4 g 1 FO (1.6 g EPA + 0.8 g DHA) | Improved MDD-related white matter deficiency |
Smith et al., 2017 [129] | MDD | Human | 260 mg or 520 mg DHA | 54% of patients showed a reduction of depression severity ≥ 50% |
Wu et al., 2018 [144] | Chemotherapy-induced depression | Rat | 1.5 g/kg omega-3 PUFAs (34% EPA + 24% DHA) | PUFAs inhibited depressive-like behaviors (p < 0.001) |
Dang et al., 2018 [133] | LPS-induced depression | Rat | 1.5 g/kg omega-3 PUFAs (34% EPA + 24% DHA) | Omega-3 PUFAs decreased depressive behavior (p < 0.001) |
Nishinaka et al., 2014 [137] | Behavioral despair paradigm | Mice | GW9508 (1.0, 10 or 25 µg/mouse) i.c.v | FFA1 activation decreased immobility in a tail suspension test (p < 0.05) |
Deyama et al., 2017 [140] | LPS-induced depression | Mice | RvD1 (10 ng i.c.v.) or RvD2 (10 ng i.c.v.) | Both treatments inhibited depressive-like behaviors (p < 0.005) |
Deyama et al., 2018 [141] | LPS-induced depression | Mice | RvE3 (10 and 100 ng i.c.v.) | Inhibition of depressive behavior (p < 0.005) |
Ishikawa et al., 2017 [142] | Chronic unpredictable stress-related depression | Mice | RvD1 (10 ng i.c.v.) or RvD2 (10 ng i.c.v.) | Both treatments inhibited depressive behavior for 24 h (p < 0.05) |
1 FO: Fish oil.